The aim of this study was to examine the anti-inflammatory effect of
abciximab-coated
stent in a porcine coronary overstretch restenosis model. Ten
abciximab-coated
stents, ten
sirolimus-eluting
stents (SES), and ten
paclitaxel-eluting
stents (PES) were deployed with oversizing (
stent/artery ratio 1.3:1) in porcine coronary arteries, and histopathologic analysis was done at 28 days after stenting. There were no significant differences in the
neointima area normalized to injury score and
inflammation score among the three
stent groups (1.58 +/- 0.43 mm(2), 1.57 +/-0.39 mm(2) in
abciximab-coated
stent group vs. 1.69 +/- 0.57 mm(2), 1.72 +/- 0.49 mm(2) in the SES group vs. 1.92 +/- 0.86 mm(2), 1.79 +/- 0.87 mm(2) in the PES group, respectively). In the
neointima, most inflammatory cells were lymphohistiocytes. Significant positive correlations were found between the extent of inflammatory reaction and the
neointima area (r=0.567, p<0.001) and percent area
stenosis (r=0.587, p<0.001). Significant correlations were found between the injury score and neointimal area (r=0.645, p<0.001), between the injury score and the
inflammation score (r=0.837, p<0.001), and between the
inflammation score and neointimal area (r=0.536, p=0.001). There was no significant difference in the inflammatory cell counts normalized to injury score among the three
stent groups (75.5 +/- 23.1/microL in abciximabcoated
stent group vs. 78.8 +/- 33.2/microL in the SES group vs. 130.3 +/- 46.9/microL in the PES group).
Abciximab-coated
stent showed comparable inhibition of inflammatory cell infiltration and neointimal
hyperplasia with other
drug-eluting stents in a porcine
coronary restenosis model.